265 related articles for article (PubMed ID: 19103565)
1. A study of rivastigmine liposomes for delivery into the brain through intranasal route.
Arumugam K; Subramanian GS; Mallayasamy SR; Averineni RK; Reddy MS; Udupa N
Acta Pharm; 2008 Sep; 58(3):287-97. PubMed ID: 19103565
[TBL] [Abstract][Full Text] [Related]
2. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.
Yang ZZ; Zhang YQ; Wang ZZ; Wu K; Lou JN; Qi XR
Int J Pharm; 2013 Aug; 452(1-2):344-54. PubMed ID: 23680731
[TBL] [Abstract][Full Text] [Related]
3. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
[TBL] [Abstract][Full Text] [Related]
4. Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2).
Degim Z; Mutlu NB; Yilmaz S; Eşsiz D; Nacar A
Pharmazie; 2010 Jan; 65(1):32-40. PubMed ID: 20187576
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Enz A; Gentsch C
Neuropharmacology; 2004 Sep; 47(3):408-13. PubMed ID: 15275830
[TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of injectable sustained-release microspheres of rivastigmine.
Zhu Y; Zhu Z; Cao Q; Chen D; Cui J
J Control Release; 2011 Nov; 152 Suppl 1():e131-2. PubMed ID: 22195801
[No Abstract] [Full Text] [Related]
7. [Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration].
Yang ZZ; Wang ZZ; Wu K; Qi XR
Yao Xue Xue Bao; 2011 Jul; 46(7):859-63. PubMed ID: 22010358
[TBL] [Abstract][Full Text] [Related]
8. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations.
Mutlu NB; Değim Z; Yilmaz Ş; Eşsiz D; Nacar A
Drug Dev Ind Pharm; 2011 Jul; 37(7):775-89. PubMed ID: 21231901
[TBL] [Abstract][Full Text] [Related]
9. Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
Shah B; Khunt D; Misra M; Padh H
Pharm Res; 2018 Jan; 35(1):8. PubMed ID: 29294189
[TBL] [Abstract][Full Text] [Related]
10. Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats.
Yang ZZ; Zhang YQ; Wu K; Wang ZZ; Qi XR
Curr Alzheimer Res; 2012 Mar; 9(3):315-25. PubMed ID: 22044027
[TBL] [Abstract][Full Text] [Related]
11. Rivastigmine exposure provided by a transdermal patch versus capsules.
Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
[TBL] [Abstract][Full Text] [Related]
12. Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
Qiang F; Shin HJ; Lee BJ; Han HK
Int J Pharm; 2012 Jul; 430(1-2):161-6. PubMed ID: 22525082
[TBL] [Abstract][Full Text] [Related]
13. In situ-forming oleogel implant for rivastigmine delivery.
Vintiloiu A; Lafleur M; Bastiat G; Leroux JC
Pharm Res; 2008 Apr; 25(4):845-52. PubMed ID: 17694395
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats.
Liang YQ; Tang XC
Acta Pharmacol Sin; 2006 Sep; 27(9):1127-36. PubMed ID: 16923332
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic rationale for the rivastigmine patch.
Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
[TBL] [Abstract][Full Text] [Related]
16. Huperzine A in rat plasma and CSF following intranasal administration.
Yue P; Tao T; Zhao Y; Ren J; Chai X
Int J Pharm; 2007 Jun; 337(1-2):127-32. PubMed ID: 17241758
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Kumar P; Kumar A
Eur J Pharmacol; 2009 Aug; 615(1-3):91-101. PubMed ID: 19445928
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine in Parkinson's disease dementia.
Lalli S; Albanese A
Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
[TBL] [Abstract][Full Text] [Related]
20. Nose-to-brain delivery of tacrine.
Jogani VV; Shah PJ; Mishra P; Mishra AK; Misra AR
J Pharm Pharmacol; 2007 Sep; 59(9):1199-205. PubMed ID: 17883890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
